Randomised double-blind placebo-controlled intervention study on the nutritional efficacy of a food for special medical purposes (FSMP) and a dietary supplement in reducing the symptoms of veisalgia

Bernhard Lieb, Patrick Schmitt

ABSTRACT

Objective To assess whether the symptoms of veisalgia can be reduced by intense water supply and the intake of antioxidative supplements and plant extracts.

Methods We performed the world’s largest randomised double-blind placebo-controlled intervention study (214 participants) on the efficacy of a food for special medical purposes (FSMP) against veisalgia symptoms. We analysed the effectiveness of: (1) an FSMP, including distinct plant extracts, vitamins and minerals, and additional (antioxidative) compounds; (2) a dietary supplement only comprising vitamins and minerals and additional (antioxidative) compounds; and (3) a placebo containing only glucose. The study followed the CONSORT (Consolidated Standards of Reporting Trials) guidelines and trial registration was not necessary.

Results Our study showed no statistically significant relationship between the variation of body water content and alcohol consumption. Contrary to common belief, the results showed that intervention with a supplement containing vitamins and minerals and additional antioxidative compounds did not lead to a statistically significant improvement in hangover symptoms. Additionally, our results confirmed a high individual variability in developing hangover symptoms depending on the amount of alcohol. Thus, standardisation of the amount of alcohol consumed in hangover studies does not necessarily contribute to the validity of the results. Finally, this study found a number of positive effects on certain hangover symptoms as a result of the FSMP, which were most likely due to the plant extracts contained within the food.

Conclusion This study significantly supports the finding that haemostasis of electrolytes and minerals caused by alcohol consumption might be negligible and that no significant dehydration due to alcohol consumption seems to occur. Additionally, only the FSMP provides evidence for a significant efficiency in the reduction of hangover symptoms such as headache and nausea following moderate and non-excessive alcohol consumption.

INTRODUCTION

Veisalgia refers to all disorders resulting from the consumption of alcohol. It comprises all physical and psychological symptoms perceived on the day after one time use of alcohol when the blood alcohol concentration is 0%. The intensity of symptoms increases while metabolic alcohol degradation progresses, culminating at 0% blood alcohol, and may persist for up to 24 hours. The symptoms are caused directly by the alcohol itself, possible congeners, and metabolic intermediates. According to Penning the most frequent impairments are exhaustion (95.5%), thirst (89.1%), fatigue (88.3%), headaches (87.7%), dry mouth (83%) and nausea (81.4%), and do not necessarily occur in a linear relationship with the amount of alcohol consumption. Various additional factors also play a decisive role in veisalgic diathesis. Thus, intra-individual gender-independent variations in the intensity and frequency of the perceived impairments occur independent of the amount of alcohol consumed. Dehydration and the concomitant loss of electrolytes is often cited in the literature as causing symptoms such as thirst and headache, but according to Ylikahri et
Figure 1  Oxidative pathways of alcohol metabolism. Alcohol is mainly converted into acetaldehyde in the cytosol by the enzyme alcohol dehydrogenase (ADH). CYP2E1 is involved in the conversion of ethanol to acetaldehyde in the endoplasmic reticulum when higher concentrations of alcohol are present. The conversion of ethanol to acetaldehyde takes place in the peroxisome via the enzyme catalase. Acetaldehyde is converted into acetate in the mitochondria by the enzyme aldehyde dehydrogenase-2 (ALDH2). The conversion of ethanol by the enzyme catalase and CYP2E1 as well as the oxidation of NADH lead to the formation of free oxygen radicals. The final products of alcohol metabolism are free oxygen radicals (ROS) (1), changes in NADH levels (2) and acetate (3). This figure is modelled after Zakhari and Zimatkin et al. 

No significant changes in electrolyte balance could be detected after alcohol consumption.8

The absorption of ethanol takes place via diffusion in the stomach, the duodenum and the distal sections of the intestine. In the duodenum or jejunum, complete ethanol uptake occurs within approximately 2 hours.9 Immediately after resorption, ethanol diffuses into tissues that have high blood supply requirements, such as the brain. Ethanol is an amphipathic solution with an oil–water distribution ratio of 1:30. Thus, ethanol is mainly distributed by the blood and the lymphatic system.9 The “first pass metabolism” pathway of ethanol encompasses all metabolic processes during resorption by the upper gastrointestinal tract or liver before the ethanol reaches the blood circulation system. In men about 9.1%, and in women about 8.4%, of the amount of alcohol consumed is metabolised via this pathway (figure 1). Ethanol is oxidised to acetaldehyde by the enzyme alcohol dehydrogenase (ADH) in the endothelia of the stomach.9 Different ADH-isoforms lead to inter-individual differences in the effectiveness of this pathway, and the capacity appears to be greater in the liver than in the stomach.10 This seems to decrease in efficiency with increasing age.11 After this process, the intracellular enzymatically regulated decay of alcohol mainly occurs within the liver. Ethanol is oxidised to the intermediate acetaldehyde by ADH, which is a reversible process but not substrate inducible. ADH converts approximately 100 mg of ethanol/kg body weight and thus correlates to a mean ethanol conversion rate of 6–9 g/hour.9 The cerebrum mainly “uses” the enzyme catalase, which is localised within peroxisomes and results in the production of acetaldehyde.12 In addition to the conversion of ethanol by ADH and catalase, other oxidases are involved within a second degradation pathway: the microsomal ethanol oxidising system (MEOS). Cytochrome P450 isoenzymes—in particular, CYP2E1, 1A2, and 3A4—contribute to ethanol metabolism in the endoplasmic reticulum of cerebral and hepatic tissues. The conversion of ethanol to acetaldehyde by CYP2E1 (figure 1) leads to the formation of free oxygen radicals—also known as reactive oxygen species (ROS)—such as hydroxyethyl, superoxide anions and hydroxyl radicals.9 13 Thus, the decay of ethanol within the cerebral tissue appears to be performed mainly by the two enzymes catalase and CYP2E1.14 Acetaldehyde is further oxidised by aldehyde dehydrogenase-2 (ALDH2, figure 1) in mitochondria, ultimately creating acetate.9 12 14 Acetaldehyde is also able to directly induce the formation of ROS by activating the NADPH oxidase NOX2, resulting in apoptosis-inducing cell membrane damage.15 Additionally, CYP2E1 expressed within the brain leads to the formation of ROS—for example, 1-hydroxyethyl radical and hydrogen peroxide, the hydroxyl radical, and the superoxide anion—during ethanol degradation.5 The reduction of NAD+ associated with ADH (figure 1) can lead to pathological concentrations of ROS in the hepatic tissue.16 Thus, the final products of alcohol metabolism are acetate, varying concentrations of NADH/H+, and ROS.

Antioxidant enzymes may play a key role in eliminating and neutralising ROS. The one-time consumption of alcohol seems to significantly reduce the concentration of antioxidants in skin.17 In general, ethanol induces the inhibition of superoxide dismutase activity in the blood plasma and hepatic tissue, resulting in less efficient elimination of ROS and, subsequently, causing oxidative
stress in the hepatic tissue. This oxidative stress may be increased by further ethanol-induced factors and processes: (1) the oxidative inhibition of catalase activity in the liver and brain, resulting in an accumulation of H$_2$O$_2$; (2) the induction of the hepatic enzymes glutathione peroxidase and glutathione reductase; and (3) the formation of free oxygen radicals, leading to mitochondrial dysfunction in cerebral tissue. Thus, oxidative stress induced by ethanol consumption seems to be an important factor causing hangover symptoms. Congeners like phenols, aldehydes, fusel alcohols, tannins and methanol are also believed to cause hangover symptoms. However, the overall contribution of congeners to hangover symptoms is significantly lower than that of the ethanol itself.

Acute hangover symptoms are mainly treated by different synthetic drugs, for example, acetylsalicylic acid or ibuprofen, but many nutritional substances are also used for prophylactically avoiding hangover symptoms. The latter have been tested and evaluated by various intervention studies. However, the validity of those intervention studies is often questioned due to the subjectively obtained quantitative and qualitative recordings of the intensity of perceived hangover symptoms. The combined analyses of the Acute Hangover Scale (AHS) and the Hangover Symptoms Scale (HSS) allow for standardised implementation in hangover intervention studies. The HSS is primarily suitable for surveys, while the AHS is more suitable for intervention studies. The methodological quality of intervention studies is reflected in part by a Jadad score, which is often used to evaluate clinical trials. While several natural products have been recommended for hangover treatment by diverse studies, there is no strong scientific evidence on their concrete intervention success in humans. Some studies have shown some effects, the number of participants were very low (<30 participants), placebos were not implemented, or the results were not confirmed by any statistical significance. In consequence, several studies achieved only a low Jadad index, the implications of which have been critically discussed.

We present here the first and probably world’s largest three-way, double-blind, randomised, placebo-controlled intervention trial on the nutritional efficacy of a food for special medical purposes (FSMP) in veisalgia. The main objective of this study was to evaluate whether the use of an FSMP has a significant effect on the severity of 47 hangover-associated disorders symptoms. We also wanted to analyse to what extent the plant extracts implemented in the FSMP may contribute to the alleviation of symptoms, hypothesising that most probably only the FSMP would be most efficient.

Lastly, we hypothesised a correlation between the severity of hangover symptoms in general and the amounts of alcohol consumed due to congeners included in certain beverages and fluid loss due to alcohol consumption, which has frequently been described in the literature.

### Methods

The double-blind study recruited 214 healthy adult men and women aged 18–65 years. People with chronic diseases or allergies, using any kind of drugs, being or planning to become pregnant within the next 6 months, taking regular medication, or reporting as alcoholics were excluded. Premixed solutions were handed out 45 min before and immediately after the participants drank alcohol. The solutions contained 7.5 g of powder which was dissolved in 100 mL of water.

FSMP, food for special medical purposes.

| Table 1 | Qualitative composition of the interventions: the dietary supplement, the administered vitamins and minerals solution, and the placebo |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Dietary supplement | Vitamins and minerals | Placebo |
| Plant extracts | Fruit extract (Malpighia glabra) | Magnesium citrate | Magnesium citrate |
| | Fruit extracts (Opuntia ficus indica) | Magnesium citrate | Magnesium citrate |
| | Leaf extract (Ginkgo biloba) | Magnesium citrate | Magnesium citrate |
| | Leaf extract (Salix alba) | Magnesium citrate | Magnesium citrate |
| | Root extract (Zingiber officinale) | Magnesium citrate | Magnesium citrate |
| Vitamins and minerals | Magnesium citrate | Magnesium citrate | Magnesium citrate |
| | Potassium chloride | Potassium chloride | Potassium chloride |
| | Sodium bicarbonate | Sodium bicarbonate | Sodium bicarbonate |
| | Zinc citrate | Zinc citrate | Zinc citrate |
| | Riboflavin | Riboflavin | Riboflavin |
| | Thiamine | Thiamine | Thiamine |
| | Hydrochloride | Hydrochloride | Hydrochloride |
| | Folic acid | Folic acid | Folic acid |
| Additional compounds | Steviol glycosides | Steviol glycosides | Steviol glycosides |
| | Inulin | Inulin | Inulin |
| | Glucose | Glucose | Glucose |
| | Flavour | Flavour | Flavour |

The complete FSMP includes all components, whereas the second intervention omits plant extracts and the placebo solely contains sugar. Additional compounds are only relevant to taste. Each composition contained 7.5 g of powder which was dissolved in 100 mL of water.
received a dietary supplement which consisted of the FSMP contents minus the plant extracts of the FSMP. The placebo exclusively contained an aromatised glucose solution. All interventions were flavoured and optically blinded with food colouring.

Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants. Randomization was performed by the software Randlist from datinf GmbH according to Schulz et al for 300 participants.

Beverages provided were “standard” beer (4.8% alcohol), mixed beer (Radler; 2.5% alcohol), white wine (11% alcohol), and white wine spritzer (50% sparkling water, 50% wine; 5.5% alcohol). Each participant was free to choose. The participants were not allowed to consume alcohol before or after the experiment. The amount of alcohol consumed during the study was up to each participant (see online supplementary file), but participants were observed to avoid any excessive misuse. The participants had to be sober at the beginning of the study and were not allowed to consume further alcohol after the first phase. Small meals were allowed during phase 1. Smoking outside the laboratory was permitted, but was documented and is reflected within the results. All participants were allowed to drop out at any time. The study was carried out in a constantly illuminated room, comfortably air-conditioned at 20°C. The distinct phases of the study are described in figure 2: (1) first measurement, (2) consumption, (3) sobering up, and (4) second measurement phase. All anthropometric characteristics measured and calculated are listed in table 2.

All participants were tested for alcohol consumption before the experiment by performing a breath alcohol test (Alcofind DA-8000). Urine and vital parameters of all participants were examined using AtlasHome urine test strips. The concentrations of glucose, ketone, proteins, blood, nitrite and leucocytes were measured, as well as the pH value and the specific mass. The type and number of alcoholic and non-alcoholic drinks consumed by each person as well as their restroom-visiting frequencies were documented. After 4 hours, the previous measurements were taken again and the second interventions were given. All participants were advised to go home, sleep, and return

### Table 2 Anthropometric comparison of the intervention groups

|                | FSMP (n=69) | Vitamins and minerals (n=76) | Placebo (n=69) |
|----------------|-------------|------------------------------|----------------|
| Male (%)       | 65          | 53                           | 50             |
| Female (%)     | 35          | 47                           | 50             |
| Mean age (years) | 25.98±6.73 | 25.59±8.51                  | 24.52±5.78     |
| Average body mass index (kg/m²) | 24.38±3.42 | 23.90±2.70                  | 23.96±3.47     |
| Average body weight (kg)       | 77.1±12.59  | 74.8±12.83                  | 73.1±13.41     |
| Average body water (%)         | 53±0.04     | 53±0.06                     | 52±0.05        |
| Average body fat (%)           | 23±0.07     | 23±0.07                     | 23±0.07        |
| Average body musculature (%)   | 40±0.04     | 39±0.04                     | 39±0.04        |

Anthropometric parameters including gender, age and body mass index (kg/m²) are shown. Additionally, fat, muscle and body water contents of participants (n=number) are shown as percentages and mean values, respectively. Standard deviations are indicated as well. FSMP, food for special medical purposes.
back to the laboratory for a third follow-up examination at 9:00 am the next day. In order to exclude unauthorised alcohol consumption during the night and to ensure that the volunteers’ blood alcohol concentrations were at 0%, breath alcohol concentration was measured when the volunteers returned the next morning. The determined alcohol concentrations were compared with theoretical values calculated on the basis of the amount of alcohol consumed and the biometric data obtained according to the Widmark formula. Additionally, the participants were asked to answer a standardised questionnaire to record the type and intensity of their perceived hangover symptoms. The qualitative assessment of the individually experienced 47 hangover symptoms was done according to the classification systems of Penning et al. The symptoms were evaluated using a scale of 0–10 points (0=no complaints, 10=severe). An extended AHS (see below) was calculated for each participant as a sum of each individual statement. The p values were calculated for all groups and parameters by a two-sample heteroskedastic t-test.

In order to calculate the oxidative capacity of the interventions and the congeners of drinks provided, the ORAC (oxygen radical absorbance capacity) values were determined by SGS Fresenius GmbH. The water content of the participants was determined before the start of the test, after the consumption phase and during the follow-up examination after the sobering phase. The water content was determined with an analytical balance and calculated according to standard mathematical formulas. The antioxidative capacity of the skin tissue was determined by multiple spatially resolved reflection spectroscopy using a medically validated hand scanner from Biozoom Services GmbH. The sevenfold measurements were carried out on the Thenar. The antioxidative capacity of the skin tissue was expressed during the measurement in standardised sizes from 0 (low) to 12 (high). The experimentally determined standard deviations were calculated (SD 0.0127). All measurements were carried out on a balance with a constant pressure of 7.85 Newtons. The change in the antioxidative capacity was determined by dividing the antioxidative capacity of the skin tissue determined before the start of the experiment by the antioxidative capacity of the skin tissue determined during the follow-up examination the next morning. The resulting value was compared with the amount of alcohol consumed using linear regression.

RESULTS
The study was performed as a double-blind placebo-controlled randomised crossover assay. We tested three different compounds: (1) a complete FSMP mixture; (2) an incomplete FSMP mixture (dietary supplement with vitamins and minerals but without plant extracts); and (3) a placebo (glucose). The proportions of male and female participants and other data such as mean values of age, body weight and body mass index are shown in Table 2.

The mean values of all parameters measured were nearly equal between all the groups. The FSMP intervention group consumed an average of 1.54 g of alcohol/kg body weight. The average alcohol consumption rate was 0.62 mL of alcohol/min. The vitamin and mineral group consumed an average of 1.57 g of alcohol/kg body weight. The average alcohol consumption rate was 0.62 mL/min. The placebo group consumed an average of 1.63 g of alcohol/kg body weight. The average alcohol consumption rate was 0.62 mL of alcohol/min. Of the participants, 22% smoked and 26% had a meal during the evening (see online supplementary table 2). For the 47 reported symptoms, the mean values, standard deviations and statistical significance of total intensity (extended AHS total score) scores for all three intervention groups were calculated and compared with each other (table 3).

With regard to the detected intensities of the hangover symptoms, the extended AHS total scores were calculated. However, the respective error rates were very high, and thus no significant conclusions could be drawn. However, the calculated mean intensity levels of some specific symptoms revealed significant results. The headache intensity of the FSMP group had a mean value of 1.99, whereas the headache intensity for the placebo group was 2.97. Thus, the average headache intensity was reduced by 34% (FSMP 1.99, vitamins and minerals 2.34, placebo 2.97), showing a p value of 0.033. In contrast, the vitamins and minerals group did not show any statistically significant effect on reducing headache intensity. Within the FSMP group, a mean intensity of 1.17 was observed for nausea. The placebo group showed a mean intensity for nausea of 2.03. Thus, the use of the FSMP resulted in an average nausea reduction of 42% (FSMP 1.17, vitamins and minerals 2.62, placebo 2.03) compared with the placebo group, with a p value of 0.036. This pain reduction might be regarded as statistically significant in some way, although for the dietary supplement group there was no statistically significant reduction in nausea compared with the placebo group. In the case of the vitamin and mineral group, however, there was no statistically significant reduction in nausea compared with the placebo group. Furthermore, the FSMP group showed statistically significant reductions in the mean intensities of indifference (p value 0.037) and restlessness (p value 0.027) compared with the placebo group (for absolute values see table 3). The mean intensity of indifference was reduced by 27% to 2.59 (vitamins and minerals 3.37, placebo 2.82), and the mean intensity of restlessness by 41% to 1.04 compared with the placebo group (vitamins and minerals 1.55, placebo 1.76). The vitamins and minerals groups, again, showed no statistically significant reductions in symptoms. All other symptoms did not show any significant differences or reductions.

The quantitative analysis referring to the effect strength/quality of the intervention showed that the FSMP group reported a mean effectiveness value of 4.22 and the vitamins and minerals group reported a value of
Table 3  Extended Acute Hangover Scale for all analysed symptoms

| Symptoms                          | FSMP (n=69) mean values | SD | P value | Vitamins and minerals (n=76) mean values | SD | P value | Placebo (n=69) mean values | SD |
|-----------------------------------|--------------------------|----|---------|------------------------------------------|----|---------|---------------------------|----|
| Thirst                            | 5.32                     | 2.69| 0.34    | 5.72                                     | 2.43| 0.97    | 5.74                      | 2.44|
| Exhaustion                        | 4.81                     | 2.54| 0.63    | 4.74                                     | 2.44| 0.75    | 4.61                      | 2.35|
| Fatigue                           | 5.68                     | 2.56| 0.51    | 6.07                                     | 2.35| 0.72    | 5.93                      | 2.31|
| Drowsiness                        | 4.64                     | 2.71| 0.57    | 4.99                                     | 2.54| 0.75    | 4.86                      | 2.44|
| Headache                          | 1.99                     | 2.49| 0.03    | 2.34                                     | 2.91| 0.19    | 2.97                      | 2.87|
| Dry mouth                         | 3.83                     | 3.33| 0.47    | 4.43                                     | 2.82| 0.62    | 4.2                       | 2.81|
| Nausea                            | 1.17                     | 2.07| 0.04    | 2.62                                     | 8.19| 0.55    | 2.03                      | 2.64|
| Weakness                          | 3.33                     | 2.51| 0.88    | 3.66                                     | 2.79| 0.56    | 3.40                      | 2.59|
| Attention (↓)                     | 4.14                     | 2.59| 0.53    | 4.33                                     | 2.8 | 0.31    | 3.86                      | 2.77|
| Concentration (↓)                 | 3.59                     | 2.57| 1.00    | 4.01                                     | 2.94| 0.37    | 3.59                      | 2.67|
| Indifference                      | 2.59                     | 2.60| 0.04    | 3.37                                     | 2.91| 0.80    | 3.57                      | 2.82|
| Responsiveness (↓)                | 3.32                     | 2.58| 0.84    | 3.78                                     | 2.58| 0.2     | 3.23                      | 2.52|
| Appetite (↓)                      | 2.39                     | 2.95| 0.09    | 2.82                                     | 2.92| 0.34    | 3.33                      | 3.47|
| Skills (↓)                        | 3.06                     | 2.69| 0.78    | 3.37                                     | 2.66| 0.68    | 3.19                      | 2.76|
| Excitement                        | 0.91                     | 1.70| 0.22    | 0.93                                     | 1.46| 0.21    | 1.29                      | 1.9 |
| Dizziness                         | 1.84                     | 2.44| 0.27    | 2.36                                     | 2.80| 0.99    | 2.33                      | 2.77|
| Memory problems                   | 2.2                      | 2.93| 0.84    | 2.25                                     | 2.81| 0.76    | 2.10                      | 2.90|
| Gastrointestinal complaints       | 1.36                     | 2.14| 0.32    | 1.43                                     | 2.28| 0.42    | 1.77                      | 2.62|
| Fuzziness                         | 2.14                     | 2.13| 0.44    | 2.21                                     | 2.36| 0.36    | 1.86                      | 2.28|
| Stomach pain                      | 0.99                     | 2.15| 1.00    | 1.00                                     | 1.95| 0.97    | 0.99                      | 2.12|
| Trembling                         | 1.59                     | 2.58| 0.85    | 1.49                                     | 2.31| 0.96    | 1.51                      | 2.32|
| Impaired balance                  | 1.74                     | 2.25| 0.58    | 1.78                                     | 2.25| 0.63    | 1.97                      | 2.60|
| Restlessness                      | 1.04                     | 1.68| 0.03    | 1.55                                     | 2.08| 0.55    | 1.76                      | 2.03|
| Chills                            | 0.23                     | 0.83| 0.16    | 0.13                                     | 0.53| 0.05    | 0.57                      | 1.77|
| Sweating                          | 1.04                     | 2.11| 0.75    | 0.96                                     | 1.64| 0.94    | 0.94                      | 1.53|
| Disorientation                    | 0.9                      | 1.87| 0.52    | 1.21                                     | 1.86| 0.78    | 1.12                      | 2.08|
| Noise sensitivity (↑)             | 1.26                     | 2.21| 0.37    | 1.32                                     | 2.03| 0.42    | 1.62                      | 2.53|
| Light sensitivity (↑)             | 1.83                     | 2.54| 0.26    | 1.95                                     | 2.53| 0.39    | 2.32                      | 2.6 |
| Emotional dulling                 | 1.12                     | 1.95| 0.21    | 1.85                                     | 2.81| 0.53    | 1.58                      | 2.35|
| Muscle pain                       | 0.62                     | 1.6 | 0.08    | 1.11                                     | 2.00| 0.75    | 1.22                      | 2.26|
| Palatability                      | 1.46                     | 2.08| 0.29    | 1.57                                     | 2.09| 0.43    | 1.87                      | 2.47|
| Cntrition                         | 0.59                     | 1.61| 0.14    | 1.22                                     | 2.26| 0.78    | 1.12                      | 2.42|
| Confusion                         | 0.84                     | 1.79| 0.41    | 1.14                                     | 2.13| 0.9     | 1.1                       | 1.96|
| Guiltiness                        | 0.42                     | 1.48| 0.18    | 0.47                                     | 1.30| 0.21    | 0.84                      | 2.09|
| Gastric irritation                | 1.49                     | 2.41| 0.75    | 1.30                                     | 2.14| 0.4     | 1.62                      | 2.44|
| Impulsivity (↑)                   | 0.96                     | 1.74| 0.26    | 1.00                                     | 1.83| 0.32    | 1.31                      | 1.91|
| Heat/cold flushes                 | 0.87                     | 2.13| 0.18    | 0.82                                     | 1.48| 0.08    | 1.36                      | 2.11|
| Vomit                             | 0.37                     | 1.21| 0.53    | 0.24                                     | 0.73| 0.21    | 0.54                      | 1.83|
| Palpitations                      | 0.94                     | 1.89| 0.59    | 0.93                                     | 1.66| 0.54    | 1.12                      | 1.91|
| Depressive mood                   | 0.61                     | 1.43| 0.15    | 0.74                                     | 1.56| 0.32    | 1.04                      | 2.07|
| Heart pains                       | 1.14                     | 1.83| 0.14    | 0.96                                     | 1.54| 0.03    | 1.67                      | 2.27|
| Tinnitus                          | 0.51                     | 1.26| 0.77    | 0.32                                     | 0.87| 0.23    | 0.58                      | 1.63|

Continued
The placebo group reported a mean effect value of 3.10 (table 2). The mean perceived effect strength of the FSMP intervention was 36% higher than that of the placebo group (p=0.024) and 14% smaller in the vitamins and minerals group (p=0.34). Only the first result with a p value of 0.02 can be regarded as statistically significant.

In order to evaluate whether a significant dehydration process could be observed and whether this process might be correlated with the amount of alcohol consumed, the relative changes in water content and the antioxidant capacity of the skin were examined (see Methods). Both parameters were determined before and after the intervention was examined. However, for all intervention groups only minor to no linear relationships could be observed.

**DISCUSSION**

According to Montrastruc, alcohol consumption is associated with increased water excretion (20 mL/g ethanol); thus, alcohol-related dehydration might be postulated as being one of the main reasons for most hangover symptoms. In our study, we could not show any statistically significant relationship between variations in body water content and alcohol consumption. Our results suggest that alcohol-induced increased fluid excretion does not necessarily lead to a significant dehydration process. On the contrary, this effect might represent a subjective perception of increased water loss. Objectively, an increased intake of fluids simply causes an increased excretion of fluids. Thus, the hypothesis that alcohol-induced dehydration is a cause for the expression of hangover symptoms such as headache cannot be supported. Instead, dehydration is more likely to be excluded as a cause for any hangover symptoms. Alcohol consumption is also believed to interfere with the haemostasis of electrolytes and minerals. However, we showed that the intervention with electrolytes, vitamins and minerals did not lead to any statistically significant improvement of or relief from hangover symptoms. Thus, haemostasis of electrolytes and minerals might be not be significantly affected by alcohol consumption. This strongly supports the findings of Ylikahri et al. and Penning et al. who also could not detect any changes in electrolyte haemostasis in relation to alcohol consumption. Any correlation between the amount of consumed alcohol and the relative changes in antioxidant capacity in the skin as published by Darvin et al. and that even one-time alcohol consumption reduces the antioxidant capacity of the skin, could not be proven. Thus, it seems to be clear that hangover symptoms are predominantly caused by alcohol and its metabolites (see Introduction). Thus, the intervention study performed

| Symptoms                  | Placebo (mean ± SD) | Vitamins and minerals (mean ± SD) | FSMP (mean ± SD) |
|---------------------------|---------------------|-----------------------------------|------------------|
| Nystagmus                 | 0.56 ± 1.50        | 0.67 ± 1.34                       | 3.10 ± 1.365     |
| Irritability              | 1.29 ± 2.18        | 1.26 ± 2.11                       | 4.22 ± 1.48      |
| Breathing problems        | 0.59 ± 1.47        | 0.72 ± 1.88                       | 3.67 ± 1.30      |
| Anxiety                   | 0.17 ± 0.98        | 0.29 ± 1.14                       | 0.88 ± 0.72      |
| Suicidal thoughts         | 0.01 ± 0.12        | 0.09 ± 0.60                       | 83.38 ± 55.53    |
| AHS total score           | 92.08 ± 57.54      | 96.36 ± 64.63                     | 92.08 ± 57.54    |

The mean values of the intensities from 0 (no complaints) to 10 (extreme complaints) of 47 hangover symptoms and the extended AHS total scores with the respective standard deviations (SD) and the statistical significances (P value) of all three intervention groups are given. Conspicuous/significant parameters are highlighted in grey; (↑) indicates increase(d), and (↓) indicates decrease(d).

AHS, Acute Hangover Scale; FSMP, food for special medical purposes.

| Symptoms                  | Placebo (n=69) | Vitamins and minerals (n=76) | FSMP (n=69) |
|---------------------------|----------------|-----------------------------|-------------|
| Nystagmus                 | 0.56 ± 1.50    | 0.67 ± 1.34                  | 3.10 ± 1.365|
| Irritability              | 1.29 ± 2.18    | 1.26 ± 2.11                  | 4.22 ± 1.48 |
| Breathing problems        | 0.59 ± 1.47    | 0.72 ± 1.88                  | 3.67 ± 1.30 |
| Anxiety                   | 0.17 ± 0.98    | 0.29 ± 1.14                  | 0.88 ± 0.72 |
| Suicidal thoughts         | 0.01 ± 0.12    | 0.09 ± 0.60                  | 83.38 ± 55.53|
| AHS total score           | 92.08 ± 57.54  | 96.36 ± 64.63                | 92.08 ± 57.54 |

The intervention groups were asked how much they observed the perceived effects of the received intervention on a scale from 0 (no effect) to 10 (extremely strong effect). The respective numbers (n) within each group are given and the standard deviations are calculated.

FSMP, food for special medical purposes.

### Table 4 Assessment of the effect inferred by the participants: did the participants feel an effect by the interventions taken?

| Intervention | Mean ± SD | P value |
|--------------|-----------|---------|
| FSMP (n=69)  | 4.22 ± 1.48 | 0.02    |
| Vitamins and minerals (n=76) | 2.67 ± 1.30 | 0.34 |
| Placebo (n=69) | 3.10 ± 1.365 | –       |

The intervention groups were asked how much they observed the perceived effects of the received intervention on a scale from 0 (no effect) to 10 (extreme complaints). The respective numbers (n) within each group are given and the standard deviations are calculated.

FSMP, food for special medical purposes.
with the FSMP, food hints at a significant reduction in headache intensities by approximately 34%, nausea by 42%, indiffERENCE by 27%, and restlessness by 41%. The intervention group receiving the dietary supplement without the plant extract compounds did not show any statistically significant differences from the placebo group.

Polyphenols from the seeds of *Trigonella foenumgraecum* lead to increased activity of the enzymes ADH and ALDH in the liver. Polyphenols from the pulp and husk of *Magnifera indica* have been shown to decrease blood plasma alcohol levels in mice by increasing the activity of ADH and ALDH. Flavonoids from *Asparagus officinalis* can also reduce alcohol toxicity by upregulating the enzymatic activities of ADH and ALDH, and the same has been shown in mice for linoleic acid derived from *Panax ginseng* and polyphenols from the fruits of *Pyrus pyrifolia*. In contrast, the application of an extract of *Plectranthus* species reduces the activity of ADH and acetylcholinergic activity, which leads to a reduced accumulation of acetaldehyde, since acetaldehyde dehydrogenase activity, which leads to a reduced accumulation of acetaldehyde, since acetaldehyde dehydrogenase activity is not lowered. Flavones and phenols from *Opuntia ficus indica* appear to reduce hangover related symptoms by inhibiting the secretion of inflammatory mediators. Flavones and phenols from the leaves and fruits of *Diospyros kaki* are shown to contribute to the prevention of alcohol-induced liver damage and reduced fat accumulation in mice by activating the antioxidant system. For ginkgolide B from the leaves of *Ginkgo biloba*, neuroprotective properties can be detected. This is justified by the inhibition of serine and aspartyl protease as well as by the antioxidant activity. Ginkgolide B inhibits dose-dependent ethanol-induced apoptosis and reduces cellular damage, which might be explained by an increased expression of NADPH oxidases in parallel to an inhibition of ethanol-induced caspase-3 expression. As a result of the antioxidant properties of *Zingiber officinale* extracts, hepatoprotective effects have been shown in detail, and also seem to protect against histological changes in the liver, kidneys, and lungs. A number of the latter substances are essential ingredients of the FSMP. Thus, it can be assumed that the effects observed in the context of this study are mainly due to the plant extracts contained therein. The underlying mechanisms remain to be unravelled and surely need further investigation. Finally, this study significantly supports the finding that the haemostasis of electrolytes and minerals inferred by alcohol consumption might not be as strongly affected as believed, as any significant dehydration process due to (moderate) alcohol consumption also could not be observed and thus cannot be corroborated.

### Acknowledgements
We thank an anonymous proof reader for helpful comments.

### Contributors
PS and BL designed the study. PS performed execution. Analyses were done by PS and BL. The manuscript was written by BL.

### Funding
This study was partly supported by a European FSMP manufacturer which provided drinks and supplements. Special funding did not occur because the study was part of a masters thesis.

### Competing interests
None declared.

### Patient consent for publication
Not required.

### Provenance and peer review
Not commissioned; externally peer reviewed.

### Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.

### Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

### REFERENCES
1. van Schrojenstein Lantman M, van de Loo AJ, Mackus M, et al. Development of a definition for the alcohol hangover: consumer descriptions and expert consensus. *Curr Drug Abuse Rev* 2016;9:148–54.
2. Verster JC, Stephens R, Penning R, et al. The Alcohol Hangover Research Group consensus statement on best practice in alcohol hangover research. *Curr Drug Abuse Rev* 2010;3:116–26.
3. Wiese JG, Shlipak MG, Browner WS. The alcohol hangover. *Ann Intern Med* 2000;132:897–902.
4. Pratt G, Adan A, Sánchez-Turet M. Alcohol hangover: a critical review of explanatory factors. *Hum Psychopharmacol* 2009;24:259–67.
5. Penning R, McKinney A, Verster JC. Alcohol hangover symptoms and their contribution to the overall hangover severity. *Alcohol Alcohol* 2012;47:248–52.
6. Haas SL, Feick P, Singer MV. Hangover symptoms after alcohol consumption: epidemiology, risk factors and pathophysiology. *Sucth* 2006;52:317–26.
7. Slutske WS, Plassceki TM, Hunt-Carter EE. Development and initial validation of the hangover symptoms scale: prevalence and
correlates of hangover symptoms in college students. *Alcohol Clin Exp Res* 2003;27:1422–50.
8 Ylikahri RH, Leino T, Huttenun MO, et al. Effects of fructose and glucose on ethanol-induced metabolic changes and on the intensity of alcohol intoxication and hangover. *Eur J Clin Invest* 1976;6:93–102.
9 Singer M, Batra A, Mann K. *Alcohol und Tabak – Grundlagen und Folgeerkrankungen*. Stuttgart: Georg Thieme Verlag, 2011: 73–88.
10 Lee DI, Kim ST, Lee DH, et al. Ginsenoside-free molecules from steamed dried ginseng berry ameliorate hangover symptom: an alternative choice for an alcohol hangover. *J Food Sci* 2014;79:C1323–30.
11 Meier P, Seitz HK. Age, alcohol metabolism and liver disease. *Curr Opin Clin Nutr Metab Care* 2008;11:21–6.
12 Deltrich RA, Petersen D, Vasiliev O. Removal of acetaldehyde from the body. In: Chadwick DJ, Goode J, eds. *Novartis Foundation symposium*. New York: John Wiley, 2007: 23–40.
13 Zakhari S. Alcohol metabolism and epigenetics changes. *Alcohol Res* 2013;35:1–5.
14 Zimackin SM, Pronko SP, Vasiliev O, et al. Enzymatic mechanisms of ethanol oxidation in the brain. *Alcohol Clin Exp Res* 2006;30:1500–5.
15 Brandt M, Garlapati V, Oelze M, et al. NOX2 amplifies acetaldehyde-mediated cardiomyocyte mitochondrial dysfunction in alcoholic cardiomyopathy. *Sci Rep* 2016;6:32554.
16 Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. *Adv Pharmacol* 97:601–28.
17 Darvish ME, Monirpour M, Kordi J, et al. Alcoholic consumption decreases the protection efficiency of the antioxidant network and increases the risk of sunburn in human skin. *Skin Pharmacol Physiol* 2013;26:45–51.
18 Pigeote E, Coribisier P, Houbion A, et al. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and on radicals. *Mech Ageing Dev* 1990;51:283–97.
19 Bindu MP, Sreekant KS, Annamalai PT, et al. Effect of S-alliin cysteine sulfoxide on lipid metabolism and free radical scavengers in alcohol fed rats. *Curr Sci* 2002;82:628–31.
20 Das SK, Vasudevan DM. Effect of ethanol on liver antioxidant defense systems: a dose dependent study. *Indian J Clin Biochem* 2005;20:80–4.
21 Karadagian AG, Bustamante J, Czerneckiczky A, et al. Alcohol hangover induces mitochondrial dysfunction and free radical production in the mouse cerebellum. *Neuroscience* 2015;304:47–59.
22 Stephens R, Ling J, Heffernan TM, et al. A review of the literature on the cognitive effects of alcohol hangover. *Alcohol Alcohol* 2008;43:163–70.
23 Rohsenow DJ, Howland J. The role of beverage congener in hangover and other residual effects of alcohol intoxication: a review. *Curr Drug Abuse Rev* 2010;3:76–9.
24 Pittler MH, Verster JC, Ernst E. Interventions for preventing or treating alcohol hangover: systematic review of randomised controlled trials. *BMJ* 2005;331:1515–6.
25 Rohsenow DJ, Howland J, Minsky SJ, et al. The acute hangover scale: a new measure of immediate hangover symptoms. *Addict Behav* 2007;32:1314–20.
26 Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.
27 Pittler MH, White AR, Stevinson C, et al. Effectiveness of artichoke extract in preventing alcohol-induced hangovers: a randomised controlled trial. *CMAJ* 2003;169:1269–73.
28 Wiese J, McPherson S, Odden MC, et al. Effect of Opuntia ficus indica on symptoms of the alcohol hangover. *Arch Intern Med* 2004;164:1334–40.
29 Schulz KE, Grimes DA. Reihe Epidemiologi 6: Generierung von Randomisierungstests in randomisierten Studien: Zufall, nicht Auswahl. *Lancet* 2002;359:515–9.
30 Schulz K, Altman D, Moher D. Consort 2010: Aktualisierte Leitlinie für Berichte randomisierter Studien im Parallelgruppen-Design. *Dtsch Med Wochenschr* 2011;136:e26–23.
31 Widmark EMP. Principles and applications of medicolegal alcohol determination (Basel RC, trans). Davis: Biomedical Publications, 1981.
32 Montrastruc P, Lácool exager la soif. HCEIA Informations 1986;4:1–2.
33 Ottervanger JH, van Nuland M, Fliervoet LAL, et al. The pathology of alcohol hangover. *Curr Drug Abuse Rev* 2010;3:68–75.
34 Kaviarasaran S, Anuradha CV, Fenugreek (Trigonella foenum graecum) seed polyphenols protect liver from alcohol toxicity: a role on hepatic detoxification system and apoptosis. *Pharmazie* 2007;62:299–304.
35 Kim S-H, K Cho S, Min T-S, et al. Ameliorating effects of mango (Mangifera indica L) fruit on plasma ethanol level in a mouse model assessed with H-NMR based metabolic profiling. *J Clin Biochem Nutr* 2011;48:214–21.
36 Kim B-Y, Cui Z-G, Lee S-R, et al. Effects of Asparagus officinalis extracts on liver cell toxicity and ethanol metabolism. *J Food Sci* 2009;74:H204–8.
37 Dembitsky VM, Poovarodom S, Leontowicz H, et al. The multiple nutrition properties of some exotic fruits: biological activity and active metabolites. *Food Res Int* 2011;44:1671–701.
38 Brito E, Gomes E, Falé PL, et al. Bioactivities of decoctions from Plectranthus species related to their traditional use on the treatment of digestive problems and alcohol intoxication. *J Ethnopharmacol* 2018;220:147–54.
39 Wiese JG, Mcpherson S, Shipilak MG. The effect of Opuntia ficus indica on the severity of the alcohol hangover. *J Gen Intern Med* 2002;17:134.
40 Song YS, Kim MJ, Ma J. Protective effects of persimmon leaf and fruit extracts against acute alcohol-induced hepatotoxicity. *Prev Nutr Food Sci* 2007;12:202–8.
41 Brunetti L, Orlando G, Menghini L, et al. Ginkgo biloba leaf extract reverses amyloid beta-peptide-induced isoprostane production in rat brain in vitro. *Planta Med* 2006;72:1296–9.
42 Zhang C, Tian X, Luo Y, et al. Ginkgolide B attenuates ethanol-induced neurotoxicity through regulating NADPH oxidases. *Toxicology* 2011;287:124–30.
43 Nwozo SO, Osumanwudia DA, Oyinloye BE. Anti-fatty liver effects of oils from Zingiber officinalis and Curcuma longa on ethanol-induced fatty liver in rats. *J Integr Med* 2014;12:59–65.
44 Shirpoor A, Rezaei F, Fard AA, et al. Ginger extract protects rat’s kidneys against oxidative damage after chronic ethanol administration. *Biomed Pharmacother* 2016;84:698–704.
45 Shamhugam KR, Ramakrishna CH, Mallikarjuna K, et al. Protective effect of ginger against alcohol-induced renal damage and antioxidant enzymes in male albino rats. *Indian J Exp Biol* 2010;48:143–9.
46 Shirpoor A, Gharalari FH, Rasm Y, et al. Ginger extract attenuates ethanol-induced pulmonary histological changes and oxidative stress in rats. *J Biomed Res* 2017;31:521–7.